These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31172606)

  • 41. Antitumor activity of cell-penetrant kinin B1 receptor antagonists in human triple-negative breast cancer cells.
    Dubuc C; Savard M; Bovenzi V; Lessard A; Côté J; Neugebauer W; Geha S; Chemtob S; Gobeil F
    J Cell Physiol; 2019 Mar; 234(3):2851-2865. PubMed ID: 30132865
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
    Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
    Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK.
    Wu Q; Ma X; Jin Z; Ni R; Pan Y; Yang G
    J Ethnopharmacol; 2023 Oct; 315():116644. PubMed ID: 37196814
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pyrazole Derivatives Induce Apoptosis via ROS Generation in the Triple Negative Breast Cancer Cells, MDA-MB-468.
    Ashourpour M; Mostafavi Hosseini F; Amini M; Saeedian Moghadam E; Kazerouni F; Arman SY; Shahsavari Z
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2079-2087. PubMed ID: 34319030
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells.
    Zhou Y; Lin S; Tseng KF; Han K; Wang Y; Gan ZH; Min DL; Hu HY
    BMC Cancer; 2016 Oct; 16(1):818. PubMed ID: 27769200
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Deciphering the molecular mechanism underlying anticancer activity of coumestrol in triple-negative breast cancer cells.
    Zafar A; Singh S; Satija YK; Saluja D; Naseem I
    Toxicol In Vitro; 2018 Feb; 46():19-28. PubMed ID: 28986287
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
    Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
    Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MiR-138-5p improves the chemosensitivity of MDA-MB-231 breast cancer cell line to paclitaxel.
    Rasoolnezhad M; Safaralizadeh R; Hosseinpour Feizi MA; Banan-Khojasteh SM; Roshani Asl E; Lotfinejad P; Baradaran B
    Mol Biol Rep; 2023 Oct; 50(10):8407-8420. PubMed ID: 37620737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apoptosis Induction via ATM Phosphorylation, Cell Cycle Arrest, and ER Stress by Goniothalamin and Chemodrugs Combined Effects on Breast Cancer-Derived MDA-MB-231 Cells.
    Khaw-On P; Pompimon W; Banjerdpongchai R
    Biomed Res Int; 2018; 2018():7049053. PubMed ID: 30598998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
    Haynes BM; Cunningham K; Shekhar MPV
    BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
    Byerly JH; Port ER; Irie HY
    Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells.
    Sprouse AA; Herbert BS
    Anticancer Res; 2014 Oct; 34(10):5363-74. PubMed ID: 25275030
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gallic acid induces G1 phase arrest and apoptosis of triple-negative breast cancer cell MDA-MB-231 via p38 mitogen-activated protein kinase/p21/p27 axis.
    Lee HL; Lin CS; Kao SH; Chou MC
    Anticancer Drugs; 2017 Nov; 28(10):1150-1156. PubMed ID: 28938245
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
    Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
    Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Curcumin and paclitaxel induce cell death in breast cancer cell lines.
    Calaf GM; Ponce-Cusi R; Carrión F
    Oncol Rep; 2018 Oct; 40(4):2381-2388. PubMed ID: 30066930
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergistic effects of epoxyazadiradione (EAD) and paclitaxel against triple-negative breast cancer cells.
    Sijisha KS; Anusha R; Priya S
    Fundam Clin Pharmacol; 2024 Aug; 38(4):758-766. PubMed ID: 38482560
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 1-Chromonyl-5-Imidazolylpentadienone Demonstrates Anti-Cancer Action against TNBC and Exhibits Synergism with Paclitaxel.
    Modi K; Lawson S; Chen G; Tumuluri D; Rekhtman I; Kurtz M; Brailoiu GC; Chen QH; Lakshmikuttyamma A
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806551
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pro-apoptotic effect of Δ2-TGZ in "claudin-1-low" triple-negative breast cancer cells: involvement of claudin-1.
    Geoffroy M; Kleinclauss A; Grandemange S; Hupont S; Boisbrun M; Flament S; Grillier-Vuissoz I; Kuntz S
    Breast Cancer Res Treat; 2017 Oct; 165(3):517-527. PubMed ID: 28681173
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The ATR inhibition by Elimusertib enhances the radiosensitivity of MDA-MB-231 triple negative breast cancer in vitro.
    Guney Eskiler G; Halis H; Hamarat KF; Derlioglu RR; Ugurlu BT; Haciefendi A
    Int J Radiat Biol; 2024; 100(5):715-723. PubMed ID: 38421209
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Codelivery of anti-cancer agents via double-walled polymeric microparticles/injectable hydrogel: A promising approach for treatment of triple negative breast cancer.
    Davoodi P; Ng WC; Srinivasan MP; Wang CH
    Biotechnol Bioeng; 2017 Dec; 114(12):2931-2946. PubMed ID: 28832946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.